- Trials with a EudraCT protocol (14,142)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (117)
14,142 result(s) found for: Period.
Displaying page 2 of 708.
EudraCT Number: 2016-003561-26 | Sponsor Protocol Number: BAY1002670/15790 | Start Date*: 2017-12-14 | |||||||||||||||||||||
Sponsor Name:Bayer AG | |||||||||||||||||||||||
Full Title: A randomized, parallel-group, double-blind and placebo-controlled, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids | |||||||||||||||||||||||
Medical condition: Leiomyoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002441-30 | Sponsor Protocol Number: TV48125-CNS-30068 | Start Date*: 2017-12-19 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Mig... | |||||||||||||
Medical condition: episodic and chronic migraine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (Completed) SE (Completed) BE (Completed) DE (Completed) CZ (Completed) FI (Completed) NL (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000251-39 | Sponsor Protocol Number: TAK-994-1504 | Start Date*: 2021-08-12 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults Wi... | |||||||||||||
Medical condition: Narcolepsy With Cataplexy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) FR (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002739-17 | Sponsor Protocol Number: AN-EPI3331 | Start Date*: 2015-12-30 |
Sponsor Name:ANTHERA Pharmaceuticals, Inc. | ||
Full Title: A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine Pancr... | ||
Medical condition: Pancreatic exocrine Insufficiency due to Cystic Fibrosis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: HU (Completed) CZ (Completed) ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003062-13 | Sponsor Protocol Number: AZP01-CLI-003 | Start Date*: 2020-02-25 | |||||||||||
Sponsor Name:Millendo Therapeutics SAS | |||||||||||||
Full Title: A Phase 2b/3 study to evaluate the safety, tolerability, and effects of livoletide (AZP-531), an unacylated ghrelin analog, on food-related behaviors in patients with Prader-Willi syndrome | |||||||||||||
Medical condition: Prader-Willi Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000854-24 | Sponsor Protocol Number: VE-CIP2001/2021 | Start Date*: 2021-12-21 | |||||||||||
Sponsor Name:ALFASIGMA S.P.A. | |||||||||||||
Full Title: Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial. | |||||||||||||
Medical condition: Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture si... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BE (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002046-16 | Sponsor Protocol Number: MARS_2020 | Start Date*: 2020-11-04 |
Sponsor Name:Fakultní nemocnice Brno | ||
Full Title: A Randomised, double-blinded, placebo-controlled, multicenter study of efficacy, safety and side effects of highly diluted atropine collyrium in slowing the progression of myopia (shortsightedness)... | ||
Medical condition: Myopia in children | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001205-25 | Sponsor Protocol Number: EP0085 | Start Date*: 2025-04-25 |
Sponsor Name:UCB Biopharma SRL | ||
Full Title: An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Wi... | ||
Medical condition: Epilepsy (partial seizures with or without secondary generalization) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2016-000426-20 | Sponsor Protocol Number: 15-006 | Start Date*: 2016-09-05 | ||||||||||||||||
Sponsor Name:Jazz Pharmaceuticals | ||||||||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy | ||||||||||||||||||
Medical condition: Treatment of cataplexy in narcolepsy Treatment of excessive daytime sleepiness (EDS) in narcolepsy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) CZ (Completed) DE (Completed) ES (Completed) FR (Completed) BE (Completed) FI (Completed) HR (Completed) NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004882-10 | Sponsor Protocol Number: SAS110099 | Start Date*: 2016-08-03 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A study to compare GW815SF HFA MDI with concomitant treatment with salmeterol xinafoate DPI plus fluticasone propionate DPI and to assess long-term safety of GW815SF HFA MDI | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2013-005568-24 | Sponsor Protocol Number: NL47657-044-14 | Start Date*: 2014-05-28 |
Sponsor Name:Medisch Spectrum Twente | ||
Full Title: The reduction of Apneas in Preterm Infants: Low-Flow versus Caffeine | ||
Medical condition: Apnea Of Prematurity | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004840-51 | Sponsor Protocol Number: EIP19-NFD-401 | Start Date*: 2019-06-26 | |||||||||||
Sponsor Name:EIP Pharma, Inc. | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) | |||||||||||||
Medical condition: Early-Stage Huntington Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004763-72 | Sponsor Protocol Number: IM133-005 | Start Date*: 2012-06-26 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-945429 in Subj... | |||||||||||||
Medical condition: Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) AT (Completed) DE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001221-16 | Sponsor Protocol Number: RISSCH3024 | Start Date*: 2015-03-31 | |||||||||||
Sponsor Name:Janssen Cilag N.V./S.A | |||||||||||||
Full Title: A Prospective Study of the Clinical Outcome Following Treatment Discontinuation After Remission in First-Episode Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004534-15 | Sponsor Protocol Number: LAT-NP-001 | Start Date*: 2019-09-03 | |||||||||||
Sponsor Name:Lateral Pharma Pty Ltd | |||||||||||||
Full Title: A Phase IIa study of the efficacy and safety of oral LAT8881 in neuropathic pain | |||||||||||||
Medical condition: Neuropathic pain (NP), associated with either postherpetic neuralgia (PHN) or diabetic peripheral neuropathy (DPN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003827-38 | Sponsor Protocol Number: CL004_282 | Start Date*: 2006-05-02 |
Sponsor Name:ChemoCentryx, Inc | ||
Full Title: A Multinational Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects with Moderate to Severe Crohn’s Disease | ||
Medical condition: Subjects will be enrolled suffering from active, moderate to severe Crohn´s disease with a history of small or large bowel disease, with or without colonic disease. Their screening Crohn´s Disease ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DK (Completed) CZ (Completed) DE (Completed) HU (Completed) BG (Completed) SE (Completed) FR (Completed) BE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003174-17 | Sponsor Protocol Number: GA1405 | Start Date*: 2015-03-24 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited | ||
Full Title: A multicentre, randomised, double-blind, two arm, parallel group, placebo controlled pivotal study to assess the effect of a sodium alginate liquid suspension as add-on therapy in GORD patients wit... | ||
Medical condition: Gastro-Oesophageal Reflux Disease (GORD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-021343-41 | Sponsor Protocol Number: ME040 | Start Date*: 2014-03-21 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Effect of sapropterin on variations of blood phenylalanine and tyrosine over 24 hours and from day to day in children with phenylketonuria | ||
Medical condition: Phenylketonuria (PKU) is an autosomal recessive metabolic genetic disorder by a mutation in the gene for the enzyme phenylalanine hydroxylase (PAH), rendering it nonfunctional. Left untreated, the ... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003303-18 | Sponsor Protocol Number: rl.01.2013 | Start Date*: Information not available in EudraCT |
Sponsor Name:Gedeon Richter Polska Sp. z o. o. | ||
Full Title: Clinical phase IV study assessing the efficacy and safety of the medicinal product Groprinosin in treatment of recurrent airway inflammation in children with impaired cellular immunity and diagnose... | ||
Medical condition: Recurrent airway inflammation in children with impaired cellular immunity. | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: PL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004489-16 | Sponsor Protocol Number: V3_KET_NEG_SYMPT_SCZ | Start Date*: 2021-11-03 |
Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Psychiatrie und Psychotherapie | ||
Full Title: Ketamine for the treatment of depressive and negative symptoms in patients with schizophrenia: a randomized controlled cross-over pilot study. | ||
Medical condition: Negative and depressive symptoms of schizophrenia according to DSM-5 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
